ABSTRACT
[Figure: see text].
Subject(s)
Angiotensin-Converting Enzyme 2/metabolism , Apoptosis , Blood Platelets/metabolism , COVID-19/metabolism , Serine Endopeptidases/metabolism , A549 Cells , Adult , Blood Platelets/ultrastructure , Blood Platelets/virology , Blotting, Western , COVID-19/blood , COVID-19/virology , Female , Host-Pathogen Interactions , Humans , Male , Microscopy, Electron, Transmission , Necroptosis , SARS-CoV-2/physiologyABSTRACT
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral pandemic marked by increased risk of thrombotic events. However, the role of platelets in the elevated observed thrombotic risk in COVID-19 and utility of antiplatelet agents in attenuating thrombosis is unknown. We aimed to determine if the antiplatelet effect of aspirin may mitigate risk of myocardial infarction, cerebrovascular accident, and venous thromboembolism in COVID-19. We evaluated 22,072 symptomatic patients tested for COVID-19. Propensity-matched analyses were performed to determine if treatment with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) affected thrombotic outcomes in COVID-19. Neither aspirin nor NSAIDs affected mortality in COVID-19. Thus, aspirin does not appear to prevent thrombosis and death in COVID-19. The mechanisms of thrombosis in COVID-19, therefore, appear distinct and the role of platelets as direct mediators of SARS-CoV-2-mediated thrombosis warrants further investigation.